In his role as Head of Corporate Government Affairs, James leads engagement with the UK Government to deliver GSK’s strategic agenda, spanning R&D, Manufacturing, Commercial and Corporate aspects of GSK’s three businesses: pharmaceuticals, vaccines, and consumer. He seeks creative opportunities to partner with the Government and to mitigate risks. James is a member of the Life Science Strategy Board. James also leads global GSK advocacy on Antimicrobial Resistance (AMR). He has advised policy development on AMR at the WHO, UN, EU Commission, the O’Neill Review and National Governments. He is Vice Chair of the Industry IFPMA AMR Committee and regularly speaks on behalf of industry, building on his role in developing the Davos Declaration and 2016 UNGA Industry AMR Roadmap. In the UK, James Chairs the ABPI AMR network and the Government-Industry AMR taskforce.